Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020

Kristina Jenei; Daniel Meyers; Bishal Gyawali

doi:10.1001/jamanetworkopen.2022.53438

Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020

JAMA Netw Open. 2023 Jan 3;6(1):e2253438. doi: 10.1001/jamanetworkopen.2022.53438.

Authors

Kristina Jenei¹, Daniel Meyers², Bishal Gyawali³

Affiliations

¹ Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
² Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
³ Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.

No abstract available

Plain language summary

This cohort study examines the association between approval characteristics, clinical benefit, and prices of cancer drugs recommended for reimbursement by the Canadian Agency for Drug and Technology in Health.

MeSH terms

Antineoplastic Agents* / therapeutic use
Canada
Humans
Neoplasms* / drug therapy

Substances

Antineoplastic Agents